Asthma is associated with atherosclerotic artery changes

Izabela Tuleta*, Dirk Skowasch, Florian Aurich, Nicolas Eckstein, Robert Schueler, Carmen Pizarro, Nadjib Schahab, Georg Nickenig, Christian Schaefer, Simon Pingel

Department of Internal Medicine II–Cardiology, Pulmonology and Angiology, University of Bonn, Bonn, Germany

* izat@gmx.de

Abstract

Asthma is a chronic airway inflammation with a potential systemic impact. Atherosclerosis is a chronic inflammatory artery disease. The aim of our study was to prove if there is a correlation between the occurrence of asthma and increased atherosclerotic vessel disorders. Vessel status was compared between mild-to-moderate, severe allergic asthma and matched controls. Measurements of artery stiffness were calculated by central pulse wave velocity, ultrasonographic strain imaging and ankle-brachial index. Atherosclerotic plaque burden was assessed by colour-coded duplex sonography. Additionally, analysis of cardiovascular and asthma blood markers was conducted. Arterial stiffness expressed as an increased central pulse wave velocity and decreased circumferential and radial strains as well as the prevalence of media sclerosis were significantly higher among asthma patients compared to controls. Atherosclerotic plaque burden was relevantly increased in asthma groups vs. controls (severe asthma: 43.1%, mild-to-moderate asthma: 25.0%, control: 14.3% of study participants). Except for the elevated IgE and fibrinogen concentrations as well as leukocyte number there were no relevant differences in the blood parameters between the groups. Allergic asthma is associated with distinct atherosclerotic artery changes compared to the respectively matched control collective. The severity of asthma correlates with more pronounced pathological vessel alternations.

Introduction

Asthma is a chronic inflammatory disease of the airways. A growing body of evidence shows that asthma may affect also extrapulmonary tissue. Patients with asthma demonstrate an increased risk for cardiovascular complications [1]. Moreover, asthma is associated with functional (higher central pulse wave velocity, [2]) and structural (increased intima-media-thickness, [3]) vessel changes. However, data linking asthma with atherosclerosis are not consistent [4]. The pathomechanisms underlying asthma-related atherosclerotic arterial alternations are not clear. Some studies reported on phenomena occurring in asthma such as inflammation [5], infection [6], oxidative stress [3] or activation of blood platelets [7] as potential mechanisms leading to the acceleration of atherosclerosis in this patients' collective. Not only asthma
itself, but also the antiasthmatic drugs may have an influence on the vessel status. Specifically, application of oral cortisone in patients with severe asthma may have deleterious effects on the vasculature [8]. In contrast, inhaled cortisone used as a controller medication in mild-to-moderate asthma may act protectively on the vascular system [9]. Against this background, the aim of our present work was to evaluate functional and structural atherosclerotic vessel changes in patients with mild-to-moderate and severe asthma compared to control individuals. Additionally, we aimed to determine the levels of cardiovascular risk markers in blood.

**Material and methods**

**Patients' characteristics**

The research was conducted according to the principles of the Declaration of Helsinki and was approved by the local ethics committee at the Medical Faculty of the University of Bonn. Written informed consent has been obtained from all subjects. The study has been conducted between October 2015 and July 2016. A total of 82 consecutive outpatients with allergic asthma have been enrolled in the study during control visits in our pneumological department. Allergic asthma was defined as an increase in forced expiratory volume in 1 second (FEV1) of more than 12% following administration of short acting ß2-agonist or a decrease in FEV1 of more than 200ml in bronchial challenge test with methacholine and detection of at least three allergo-allergens in specific IgE blood measurements or in skin prick test. All patients presented stable disease without clinical exacerbation at the time point of the study performance. Patients with immunodeficiency or a history of autoimmune or other than asthma chronic inflammatory diseases were excluded. Asthma patients have been divided into two groups: mild-to-moderate (n = 24) and severe asthma (n = 58). Mild-to-moderate asthma patients were under inhaled therapy with no present or past treatment with omalizumab or oral cortisone. In contrast, severe asthma was characterized by a maximal inhaled therapy combined with a present or past administration of omalizumab and/or cortisone oral. 21 non-asthmatic patients served as controls. There were no significant differences in sex, age, body mass index and cardiovascular risk factors such as arterial hypertension, hypercholesterolemia, diabetes mellitus, nicotine abuse or history of artery disease between these three groups. Lung function showed significantly decreased absolute and predicted FEV1 values as well as significantly increased absolute and predicted total airway resistance values in asthma patients compared to controls. The exact baseline characteristic of the patients and controls is presented in the Table 1.

**Angiological measurements**

Classical parameters of vessel stiffness have been calculated by means of central pulse wave velocity (cPWV) and ankle-brachial index (ABI). Assessment of central pulse wave velocity (cPWV) was performed using AngE Pro8® (Sonotechnik Austria, Maria Rain, Austria). Ankle-brachial index (ABI), defined as the ratio of the systolic blood pressure (SBP) measured at the ankle to that measured at the brachial artery [10], was calculated for both tibial posterior artery and the dorsal pedis artery on both sides. Mean ABI values >1.3 pointed to an increased vascular stiffness and were considered as an indicator for media sclerosis [11]. Colour-coded duplex sonography was used for the detection of atherosclerotic plaques. Presence of cerebral or peripheral arterial disease was defined by ≥1 atherosclerotic plaque in the duplex sonography.

Ultrasoundographic strain imaging included global average circumferential strains (% of vessel circumference changes), global average radial strains (% of vessel wall thickness changes), radial displacement (changes in vessel wall position in mm), global average circumferential strain rates (vessel circumference changes per second) and global average radial strain rates...
Common carotid artery was shown in the two-dimensional short axis (Philips iE33). Four electrocardiography (ECG)-triggered cardiac cycles were stored for the offline analysis. Following creation of a region of interest, the frame-to-frame displacements of the speckles representing tissue movements were analyzed by using of a computer workstation equipped with a speckle-tracking software package (Image Arena Version 4.6, TomTec Systems GmbH, Munich, Germany). This method has been previously described [12, 13].

**Assessment of different blood parameters**

The following cardiovascular risk and asthma markers in blood have been examined using standard laboratory tests: total cholesterol, HDL- and LDL-cholesterol, lipoprotein(a), C-reactive protein (CRP), interleukin-6, soluble interleukin-2 receptor (sIL-2R), immunoglobulin E (IgE), fibrinogen, d-dimer, leukocytes, lymphocytes, eosinophils, hemoglobin, thrombocytes.

**Table 1. Baseline characteristic of asthma patients and controls.** Except for a significant reduced lung function and specific antiasthmatic therapy in asthma patients there were no relevant differences between asthma and control groups. BMI = body mass index. FEV1 = forced expiratory volume in 1 second, TLC = total lung capacity, RV = residual volume, Rtot = total airway resistance Data are presented as a mean ± standard error of the mean (SEM) or n (%). P<0.05 = significant.

|                  | Group 1 (Mild asthma, n = 24) | Group 1 (Severe asthma, n = 58) | Group 3 (No asthma = Control, n = 21) | P value |
|------------------|-------------------------------|---------------------------------|--------------------------------------|---------|
| Sex, male (n, %) | 7 (29.2)                      | 21 (36.2)                       | 11 (52.4)                            | 0.257   |
| Age (years)      | 46.4±2.2                      | 52.8±1.9                       | 48.3±2.7                            | 0.107   |
| BMI (kg/m^2)     | 27.0±0.9                      | 27.4±0.7                       | 25.0±0.6                            | 0.155   |
| Arterial hypertension (n, %) | 8 (33.3) | 20 (34.5) | 9 (42.9) | 0.755 |
| Hypercholesterolemia (n, %) | 5 (20.8) | 6 (10.3) | 3 (14.3) | 0.411 |
| Diabetes mellitus (n, %) | 3 (12.5) | 4 (6.9) | 0 (0.0) | 0.264 |
| Nicotine abuse   |                              |                                 |                                      | 0.110   |
| - Current (n, %) | 5 (20.8)                      | 2 (3.4)                         | 3 (14.3)                            |         |
| - Former (n, %)  | 3 (12.5)                      | 12 (20.7)                      | 2 (9.5)                             |         |
| History of coronary heart disease (n, %) | 0 (0) | 1 (1.7) | 0 (0.0) | 0.700 |
| History of peripheral arterial disease (n, %) | 5 (20.8) | 8 (13.8) | 1 (4.8) | 0.341 |
| Therapy          |                              |                                 |                                      |         |
| - Inhaled glucocorticoids n (%) | 21 (87.5) | 58 (100) | 0 (0.0) | <0.001 |
| - Long acting beta-2 agonists = LABA (n, %) | 16 (66.7) | 58 (100) | 0 (0.0) | <0.001 |
| - Long-acting muscarinic antagonists = LAMA (n, %) | 6 (25.0) | 37 (63.8) | 0 (0.0) | <0.001 |
| - Oral glucocorticoids (n, %) | 0 (0.0) | 20 (34.5) | 0 (0.0) | <0.001 |
| - Omalizumab, current (n, %) | 0 (0.0) | 47 (81.0) | 0 (0.0) | <0.001 |
| - Omalizumab, former (n, %) | 0 (0.0) | 8 (13.8) | 0 (0.0) | <0.001 |
| Lung function    |                              |                                 |                                      |         |
| - TLC (l)        | 5.7±0.3                       | 6.0±0.2                        | 6.9±0.4                             | 0.018   |
| - TLC (% predicted) | 99.9±3.3 | 101.9±1.8 | 111.4±4.6 | 0.074 |
| - FEV1 (l)       | 2.8±0.2                       | 2.3±0.1                        | 3.3±0.3                             | 0.001   |
| - FEV1 (% predicted) | 90.2±4.4 | 76.6±2.8 | 100.6±4.0 | <0.001 |
| - RV (l)         | 2.1±0.1                       | 2.7±0.1                        | 2.7±0.2                             | 0.010   |
| - RV (% predicted) | 114.0±7.4 | 135.7±5.4 | 131.6±9.9 | 0.080 |
| - Rtot (l*kPa/s) | 0.3±0.0                       | 0.4±0.0                        | 0.2±0.0                             | 0.037   |
| - Rtot (% predicted) | 105.1±13.4 | 132.0±13.5 | 64.7±8.0 | 0.038 |

https://doi.org/10.1371/journal.pone.0186820.t001
Statistical analysis

Mean values of the determined parameters ± standard error of the mean (SEM) were compared by means of ANOVA for three groups and by means of the Student’s t-test for two selected groups. Potential differences between categorical variables were calculated by using of the chi-square test. P<0.05 was considered as statistically significant.

Results

As a key finding, the angiological results have shown an increased arterial stiffness and more manifest atherosclerosis in patients with asthma, especially in those with its severe form, compared to the baseline matched controls. In detail, central pulse wave velocity differed significantly across the groups studied (mild-to-moderate asthma: 5.81±0.52 m/s, severe asthma: 6.45±0.35 m/s, control: 4.91±0.29 m/s; p = 0.019) with the highest values in severe asthma collective (p = 0.005 vs. control; Fig 1A).

Vascular strains presented a relevant decrease of circumferential strains and radial strains in severe asthma (3.18±0.23%, 3.47±0.20%, respectively) in comparison to control (4.29±0.35%; p = 0.013, 4.97±0.29%, p<0.001; resp., Fig 1C and 1D). Circumferential and radial strains were also reduced in mild-to-moderate asthma (3.78±0.42%, 4.07±0.35%), but without reaching a statistical significance vs. control (p = 0.363, p = 0.054, resp., Fig 1C and 1D). Other vascular strains, such as: radial displacement, circumferential strain rates and radial strain rates demonstrated no significant differences across the groups (p = 0.055, p = 0.101, p = 0.088, resp.), however there was a trend towards lower values of these parameters in severe asthma (0.12±0.01 mm, 0.23±0.01 1/s, 0.29±0.01 1/s, resp.) compared to control (0.16±0.01 mm, 0.28±0.03 1/s, 0.34±0.02 1/s; Fig 1B, 1E and 1F). Radial displacement tended also to be reduced in mild-to-moderate asthma (0.13±0.01 mm) vs. control (Fig 1B). Circumferential strain rates and radial strain rates showed the same mean values in mild-to-moderate asthma (0.28±0.03 1/s, 0.34±0.03 1/s, resp.; Fig 1E and 1F) as for control. Media sclerosis was more pronounced in severe (n = 39.7%) and mild-to-moderate (n = 29.2%) asthma compared to the non-asthma group (n = 9.5%; p<0.037; Fig 2).

Manifest atherosclerotic vessel changes were significantly more frequent in asthma patients, particularly in severe asthma individuals vs. controls. Specifically, atherosclerotic plaques were seen in 43.1% of severe asthma, 25.0% of mild-to-moderate asthma and 14.3% of control study participants (p = 0.035; Fig 2). Atherosclerotic artery alternations accounted for the predominance of peripheral artery disease in severe asthma (36.2%), followed by mild-to-moderate asthma (20.8%) vs. control (4.8%; p = 0.015; Fig 2). Similarly, cranial artery disease could be diagnosed more often in asthma patients (severe asthma: 25.9%; mild-to-moderate asthma: 20.8% vs. control: 14.3%), however these differences were not statistically significant (p = 0.540; Fig 2).

Next step was to determine if the above described pathological arterial alternations were accompanied by the changes in blood levels of different cardiovascular risk and asthma markers. Our results demonstrated that patients with asthma characterized by higher IgE blood concentrations (severe asthma: 7.3±1.1*100 IU/ml, mild-to-moderate asthma: 2.1±0.6*100 IU/ml, control: 0.4±0.3*100 IU/ml; p = 0.002) showed significant elevated levels of fibrinogen (severe asthma: 3.3±0.1 g/l, mild-to-moderate asthma: 3.3±0.2 g/l vs. control; p = 0.005) and leukocytes (severe asthma: 8.2±0.4 G/l, mild-to-moderate asthma: 7.0±0.4 G/l vs. control; p = 0.001) with a reduced lymphocyte fraction (severe asthma: 26.1±1.1%, mild-to-moderate asthma: 27.8±1.1% vs. control; p = 0.025) and a slightly increased number of eosinophils (severe asthma: 3.8±0.4%, mild-to-moderate asthma: 3.8±0.7% vs. control; p = 0.191) compared to control (2.7±0.1 g/l, 5.9±0.2 G/l, 32.0±1.8%, 2.4±0.4%, resp.; Fig 3).
Additionally, there was a tendency towards higher levels of lipoprotein(a) and thrombocytes in asthma patients (severe asthma: $20.5 \pm 3.3 \times 10^5 \text{ mg/dl}$, mild-to-moderate asthma: $20.2 \pm 5.9 \times 10^5 \text{ mg/dl}$; severe asthma: $27.8 \pm 0.9 \text{ G/l}$; $p = 0.05$, mild-to-moderate asthma: $28.7 \pm 1.3 \text{ G/l}$, resp.) compared to controls ($10.1 \pm 2.1 \times 10^5 \text{ mg/dl}$; $p = 0.280$, $24.1 \pm 1.0 \text{ G/l}$; $p = 0.076$, resp.; Fig 1. Diagnoes representing changes of arterial stiffness measured by central pulse wave velocity (a) and ultrasonographic strain imaging (b-f) depending on the presence of asthma. $P<0.05 = \text{significant vs. control.}$

https://doi.org/10.1371/journal.pone.0186820.g001
Interestingly, there were no relevant differences in classical cardiovascular risk factors such as cholesterol, HDL cholesterol, LDL cholesterol or inflammatory markers such as C-reactive protein (CRP) between the groups (Fig 3).

For evaluation of a potential influence of the asthma-associated medicamentous therapy, a subanalysis of patients with omalizumab and oral cortisone treatment (group 1a, n = 16) vs. patients on omalizumab without oral cortisone therapy (group 1b, n = 31) has been conducted. Baseline characteristics were similar in both groups. The only difference was that patients from group 1a had significantly lower FEV1 values in comparison with the group 1b (FEV1: $1.9\pm0.2$ l vs. $2.7\pm0.1$ l, resp., $p = 0.002$; FEV1 (% predicted): $67.0\pm5.2\%$ vs. $85.8\pm3.4\%$, resp., $p = 0.003$). Angiological examinations have shown worse vessel status with a significantly higher percentage of atherosclerotic plaques in the group 1a vs. group 1b (central pulse wave velocity: $6.87\pm0.60$ m/s vs. $5.87\pm0.46$ m/s, resp., $p = 0.194$; global radial displacement: $0.09\pm0.01$ mm vs. $0.12\pm0.01$ mm, resp., $p = 0.154$; global circumferential strain: $2.62\pm0.38\%$ vs. $3.46\pm0.34\%$, resp., $p = 0.141$; global radial strain: $3.21\pm0.37\%$ vs. $3.70\pm0.29\%$, resp., $p = 0.324$; global circumferential strain rate: $0.18\pm0.02$ vs. $0.26\pm0.02$, resp., $p = 0.029$; global radial strain rate: $0.25\pm0.02$ vs. $0.31\pm0.02$, resp., $p = 0.124$; atherosclerotic plaques: $68.8\%$ vs. $32.3\%$, resp., $p = 0.017$; cranial artery disease: $37.5\%$ vs. $19.4\%$, resp., $p = 0.176$; peripheral artery disease: $56.3\%$ vs. $29.0\%$, resp., $p = 0.069$). Blood analysis demonstrated except for increased IgE levels and most likely cortisone-associated changes in the white blood cell count in group 1a (IgE: $10.2\pm1.7^{*}10^3$ IU/ml vs. group 1b: $3.5\pm0.8^{*}10^3$ IU/ml, $p = 0.009$; leukocytes: $10.1\pm0.9$ G/l vs. $10.7\pm1.2$ G/l, resp., $p = 0.065$).

Fig 2. Increased prevalence of media sclerosis, atherosclerotic plaques as well as cerebral and peripheral artery disease in asthma patients compared to respectively matched controls. $P<0.05$ = significant across the groups.

https://doi.org/10.1371/journal.pone.0186820.g002
group 1b: 7.4±0.2 G/l, p = 0.001; lymphocytes: 21.7±2.6% vs. group 1b: 28.9±1.2%, p = 0.005) no relevant differences between both groups.

Discussion

Our data show pathological artery changes in asthma patients compared to the control collective. Specifically, asthma was not only associated with preatherosclerotic vessel alternations, such as higher arterial stiffness, but much more with increased prevalence of manifest atherosclerosis compared to non-asthma individuals. Indeed, asthma has already been described to be a risk factor for stroke and heart diseases [14,15,1]. Generally, an impaired lung function has been associated with an increased cardio- and cerebro-vascular disease risk [16,17]. Increased brachial-ankle pulse-wave velocity has been detected in stable and severe asthma patients [2]. Adult-onset asthma but not child-onset asthma was associated with an augmented carotid intima-media-thickness (IMT) among women but not men [18]. However, it has also been reported on contradictory results with no differences in aortic stiffness parameters in childhood-onset asthma compared to control patients likely due to the anti-inflammatory effect of inhaled steroids [4] or even diminished atherosclerosis in asthmatic patients as a possible consequence of elevated circulating endogenous heparin-like material [19].

As traditional cardiovascular risk factors, such as: arterial hypertension, diabetes mellitus, hypercholesterolemia, obesity and nicotine abuse were similar between asthma and control
individuals, we aimed to determine other potential risk markers in the blood. As a result, only IgE and fibrinogen levels as well as leukocyte number and subtypes differed significantly between the groups. Fibrinogen is independently linked to enhanced rates of cardiovascular complications [20]. It has been shown that persistent asthmatics have higher CRP [2] and fibrinogen levels in blood [1]. Leukocytes are the main cells of inflammation which is a hallmark of atherosclerosis [21]. In particular, high neutrophil-lymphocyte ratio (NLR) has a predictive value for future vascular events [22]. In our work we have observed a trend towards elevated lipoprotein(a) concentrations as well as thrombocyte and eosinophil counts. Increased lipoprotein(a) levels are associated with the risk of future cardiovascular disease events [23]. Activated blood platelets, in turn, may promote atherosclerosis [24]. Moreover, peripheral blood eosinophilia is a predictor factor for death from coronary heart diseases and cerebrovascular diseases [25]. Additionally, it has been shown that allergic asthma may accelerate atherosclerosis via activation of Th2 and Th17 cells in apolipoprotein E deficient mice [26].

Inversely, subcutaneous allergen-specific immunotherapy was associated with lower risk for autoimmune disease and acute myocardial infarction, as well as decreased all-cause mortality [27]. Furthermore, asthma is related to the increased arterial inflammation measured by arterial 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) images [28]. In line with this result, multiple inflammatory markers known as risk markers for atherosclerosis development were detected in asthma [29]. A positive relationship was also found between increased oxidative stress and carotid intima-media thickness in asthmatic patients [3]. Single nucleotide polymorphisms (SNPs) in some genes in asthma patients may influence levels of serum markers of inflammation and endothelial dysfunction connected to cardiovascular disease progression [30]. Other studies demonstrated further data supporting a thesis that some pathological phenomena such as leukotriene pathways [31], circulating platelet-leukocyte aggregates [32], activation of toll-like receptors (TLRs, [33]), release of platelet activating factor (PAF) from mast cells [34] or infection with *Chlamydia pneumoniae* [6] are common for asthma and atherosclerosis.

In our study, all vessel changes were more pronounced in severe asthma compared to mild-to-moderate asthma. Interestingly, patients on the add-on combined therapy of oral corticosteroid and omalizumab (group 1a) showed even greater atherosclerotic artery alternations than the patients with the same therapy except for oral corticosteroids (group 1b). Since the lung function was more impaired in group 1a vs. group 1b, it is difficult to judge if the severity of asthma, differences in the treatment or both influenced this finding. In this context, the role of antiasthmatic medication in the process of vasculopathy is not clear. Some works reported on the beneficial effects of inhaled glucocorticosteroids on the vessel changes [35]. One could think that oral cortisone due to its antiinflammatory properties, such as a direct inhibition of the expression of adhesion molecules in vascular endothelial cells [36] or of the chemotactic response of monocytes exposed to oxidized beta-VLDL [37] may also have a positive influence on the artery alternations. Contrary to this presumption, the use of oral corticosteroids was linked to an increased risk for myocardial infarction [8]. However, different animal experiments showed inconsistent results ranging from steroid-associated reduction of plaque progression [38], no effect of cortisone [39] to progression of atherosclerosis under cortisone therapy [40]. Inhibition of intracellular glucocorticoid may ameliorate metabolic syndrome and thus treat effectively atherosclerosis. Explanation of this finding could be a multifaceted nature of cortisone which contrary to the generally accepted view that cortisone acts purely anti-inflammatory may also enhance diverse inflammatory processes [41].

In our present study, we did not observe any relevant cortisone-related side effects, such as: increase in blood pressure, induction of hypercholesterolemia or diabetes mellitus. One may assume that asthma-specific activity and adverse effects of a long-term high dose cortisone
therapy may have led to the worst vessel status in patients with severe asthma under oral cortisone therapy.

In conclusions, our data implicate an association between asthma, in particular severe asthma, and pathological artery changes, including a significantly increased atherosclerotic plaque load.

**Author Contributions**

**Conceptualization:** Izabela Tuleta, Dirk Skowasch, Florian Aurich, Carmen Pizarro.

**Formal analysis:** Izabela Tuleta, Florian Aurich, Nicolas Eckstein.

**Investigation:** Florian Aurich, Nicolas Eckstein, Christian Schaefer, Simon Pingel.

**Methodology:** Florian Aurich, Nicolas Eckstein, Robert Schueler, Christian Schaefer, Simon Pingel.

**Project administration:** Dirk Skowasch.

**Resources:** Izabela Tuleta.

**Supervision:** Georg Nickenig.

**Validation:** Carmen Pizarro.

**Visualization:** Izabela Tuleta.

**Writing – original draft:** Izabela Tuleta.

**Writing – review & editing:** Izabela Tuleta, Dirk Skowasch, Nadjib Schahab.

**References**

1. Tattersall MC, Guo M, Korcarz CE, Gepner AD, Kaufman JD, Liu KJ, et al. Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015; 35: 1520–1525. https://doi.org/10.1161/ATVBAHA.115.305452 PMID: 25908767

2. Sun WX, Jin D, Li Y, Wang RT. Increased arterial stiffness in stable and severe asthma. Respir Med. 2014; 108: 57–62. https://doi.org/10.1016/j.rmed.2013.10.021 PMID: 24238772

3. Cakmak A, Zeyrek D, Cece H, Erel O. The relationship between carotid intima media thickness and oxidative stress in asthmatic children. Asian Pac J Allergy Immunol. 2010; 28: 256–261. PMID: 21337909

4. Uğur Z, Gülen F, Özürek AR. Abdominal aortic stiffness as a marker of atherosclerosis in childhood-onset asthma: a case-control study. Cardiovasc J Afr. 2015; 26: 8–12. https://doi.org/10.5830/CVJA-2014-046 PMID: 25268111

5. Cao RY, St Amand T, Gräbner R, Habenicht AJ, Funk CD. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis. 2009; 203: 395–400. https://doi.org/10.1016/j.atherosclerosis.2008.07.045 PMID: 18804760

6. Azzouzi N, Elhataoui M, Bakhatar A, Takourt B, Benslimane A. [Part of Chlamydia pneumoniae in atherosclerosis and exacerbation of chronic obstructive pulmonary disease and asthma]. Ann Biol Clin (Paris). 2005; 63: 179–194.

7. Pitchford SC, Riffle-Vasquez Y, Sousa A, Momi S, Gresele P, Spina D, et al. Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood. 2004; 103: 639–647. https://doi.org/10.1182/blood-2003-05-1707 PMID: 14504080

8. Varas-Lorenzo C, Rodríguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007; 192: 376–383. https://doi.org/10.1016/j.atherosclerosis.2006.05.019 PMID: 16786747

9. Otsuki M, Miyatake A, Fujita K, Hamasaki T, Kasayama S. Reduced carotid atherosclerosis in asthmatic patients treated with inhaled corticosteroids. Eur Respir J. 2010; 36: 503–508. https://doi.org/10.1183/09031936.00000009 PMID: 20413534

10. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al.; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on
Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012; 126: 2890–2909. Review. https://doi.org/10.1161/CIR.0b013e318276fbb PMID: 23159553

11. Hirsch M, Francesconi M, Hirsch MM. Moeneckberg media sclerosis: clinical aspects in diabetic patients. Vasa. 1991; 20: 216–221. PMID: 1950137

12. Bjällmark A, Lind B, Peolsson M, Shahgaldi K, Brodin LA, Nowak J. Ultrasonographic strain imaging is superior to conventional non-invasive measures of vascular stiffness in the detection of age-dependent differences in the mechanical properties of the common carotid artery. Eur J Echocardiogr. 2010; 11: 630–636. https://doi.org/10.1093/echojcv/eq033 PMID: 20338957

13. Larsson M, Heyde B, Kremer F, Brodin LÅ, D’hooge J. Ultrasound speckle tracking for radial, longitudinal and circumferential strain estimation of the carotid artery—an in vitro validation via sonomicrometry using clinical and high-frequency ultrasound. Ultrasound. 2014; 56: 399–408. https://doi.org/10.1016/j.ultras.2014.09.005 PMID: 25262347

14. Schanen JG, Iribarren C, Shahar E, Punjabi NM, Rich SS, Sorlie PD, et al. Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax. 2005; 60: 633–638. https://doi.org/10.1136/thx.2004.026484 PMID: 16061703

15. Iribarren C, Tolstykh IV, Eisner MD. Are patients with asthma at increased risk of coronary heart disease? Int J Epidemiol. 2004; 33: 743–748. https://doi.org/10.1093/ije/dyh081 PMID: 15131088

16. Ebi-Kryston KL. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the WHH Study. J Clin Epidemiol. 1988; 41: 251–260. PMID: 3339378

17. Truelsen T, Prescott E, Lang P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol. 2001; 30: 145–151. PMID: 11171876

18. Onufkrak S, Abramson J, Vaccarino V. Adult-onset asthma is associated with increased carotid atherosclerosis among women in the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2007; 195: 129–137. https://doi.org/10.1016/j.atherosclerosis.2006.09.004 PMID: 17045272

19. Lasser EC, Barry C, Kortman K. Diminished atherosclerotic arterial calcifications in asthma. A possible role for elevated endogenous heparin-like material. Allergy. 1987; 42: 549–552. PMID: 3688378

20. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005; 294: 1799–1809. https://doi.org/10.1001/jama.294.14.1799 PMID: 16219884

21. Schnoor M, Alcaide P, Voisin MB, van Buul JD. Crossing the Vascular Wall: Common and Unique Mechanisms Exploited by Different Leucocyte Subsets during Extravasation. Mediators Inflamm. 2015; 2015: 946509. https://doi.org/10.1155/2015/946509 PMID: 26586668

22. Paquissi FC. The role of inflammation in cardiovascular diseases: the predictive value of neutrophil-lymphocyte ratio as a marker in peripheral arterial disease. Ther Clin Risk Manag. 2016; 12: 851–860. eCollection 2016. https://doi.org/10.2147/TCRM.S107635 PMID: 27313459

23. Forbes CA, Quek RG, Deshpande S, Worthy G, Wolff R, Stirk L, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis. 2016; 15: 95. https://doi.org/10.1186/s12944-016-0258-8 PMID: 27184891

24. Adrover JM, Hidalgo A. Activated platelets jam up the plaque. Circ Res. 2015; 116: 557–559. https://doi.org/10.1161/CIRCRESAHA.115.305823 PMID: 25677512

25. Hospers JJ, Rijken B, Schouten JP, Postma DS, Weiss ST. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol. 1999; 150: 482–491. PMID: 10472948

26. Wang L, Gao S, Xu W, Zhao S, Zhou J, Wang N, et al. Allergic asthma accelerates atherosclerosis dependent on Th2 and Th17 in apolipoprotein E deficient mice. J Mol Cell Cardiol. 2014; 72: 20–27. https://doi.org/10.1016/j.yjmcc.2014.02.005 PMID: 24530901

27. Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol. 2012; 129: 413–419. https://doi.org/10.1016/j.jaci.2011.09.007 PMID: 22004944

28. Vijayakumar J, Subramanian S, Singh P, Corsini E, Fontanex S, Lawler M, et al. Arterial inflammation in bronchial asthma. J Nucl Cardiol. 2013; 20: 385–395. https://doi.org/10.1007/s12350-013-9697-z PMID: 23526206

29. Wu TL, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT. A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic
obstructive pulmonary disease. J Clin Lab Anal. 2007; 21: 367–371. https://doi.org/10.1002/jcla.20197 PMID: 18041101

30. Wilker EH, Alexeeff SE, Poon A, Litonjua AA, Sparrow D, Vokonas PS, et al. Candidate genes for respiratory disease associated with markers of inflammation and endothelial dysfunction in elderly men. Atherosclerosis. 2009; 206: 480–485. https://doi.org/10.1016/j.atherosclerosis.2009.03.004 PMID: 19409562

31. Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res. 2010; 86: 243–253. Review. https://doi.org/10.1093/cvr/cvq016 PMID: 2009252

32. Tabuchi A, Kuebler WM. Endothelium-platelet interactions in inflammatory lung disease. Vascul Pharmacol. 2008; 49: 141–150. Review. https://doi.org/10.1016/j.vph.2008.06.004 PMID: 18625343

33. Erickson B, Sperber K, Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev. 2008; 16: 273–279. https://doi.org/10.1097/CRD.0b013e3181709fd8 PMID: 18923230

34. Alevizos M, Karagkouni A, Panagiotidou S, Vasiadi M, Theoharides TC. Stress triggers coronary mast cells leading to cardiac events. Ann Allergy Asthma Immunol. 2014; 112: 309–316. https://doi.org/10.1016/j.anai.2013.09.017 PMID: 24428962

35. Otsuki M, Miyatake A, Fujita K, Hamasaki T, Kasayama S. Reduced carotid atherosclerosis in asthmatic patients treated with inhaled corticosteroids. Eur Respir J. 2010; 36: 503–508. https://doi.org/10.1183/09031936.00090009 PMID: 20413534

36. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992; 89: 9991–9995. PMID: 1279685

37. Yamada K, Naito M, Hayashi T, Asai K, Yoshimine N, Iguchi A. Effects of dexamethasone on migration of human monocytes in response to oxidized beta-very low density lipoprotein. Artery. 1993; 20: 253–267. PMID: 8141646

38. Makheja AN, Bloom S, Muesing R, Simon T, Bailey JM. Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis. 1989; 76: 155–161. PMID: 2543422

39. Cook DL, Ray G, Davison E, Feldstein LM, Calvin LD, Green DM. The effects of cholesterol dosage, cortisone, and DCA on total serum cholesterol, lipoproteins, and atherosclerosis in the rabbit. J Exp Med. 1952; 96: 27–34. PMID: 14946326

40. Stamler J, Katz LN. Effects of desoxycorticosterone acetate on cholesterolemia, blood pressure and atherogenesis in chicks. Circulation. 1951; 4: 262–269. PMID: 14859405

41. Hermanowski-Vosatk a A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005; 202: 517–527. https://doi.org/10.1084/jem.20050119 PMID: 16103409